Molecular Markers in Key Steroidogenic Pathways, Circulating Steroid Levels, and Prostate Cancer Progression - Concepedia

Concepedia

Publication | Closed Access

Molecular Markers in Key Steroidogenic Pathways, Circulating Steroid Levels, and Prostate Cancer Progression

56

Citations

28

References

2012

Year

Éric Lévesque, Shu‐Pin Huang, Étienne Audet‐Walsh, Louis Lacombe, Bo‐Ying Bao, Yves Fradet, Isabelle Laverdière, Mélanie Rouleau, Chao‐Yuan Huang, Chia‐Cheng Yu,

Clinical Cancer Research

Abstract

This study identifies, in different ethnic groups and at different disease stages, CYP17A1, HSD17B2, and ESR1 as attractive prognostic molecular markers of prostate cancer progression.

References

	Year	Citations
Global cancer statistics Ahmedin Jemal, Freddie Bray CA A Cancer Journal for Clinicians	2011	55K
Statistical significance for genomewide studies John D. Storey, Robert Tibshirani Proceedings of the National Academy of Sciences GeneticsGenomicsHigh Throughput SequencingFalse Positive RateGenome-wide Association Studies	2003	9.9K
Abiraterone and Increased Survival in Metastatic Prostate Cancer Johann S. de Bono, Christopher J. Logothetis, Arturo Molina, New England Journal of Medicine	2011	4.3K
Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth Bruce Montgomery, Elahe A. Mostaghel, Robert L. Vessella, Cancer Research	2008	1.4K
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study Howard I. Scher, Tomasz M. Beer, Celestia S. Higano, The Lancet UrologyOncologyMedicineCastration-resistant Prostate CancerAnti-cancer Agent	2010	1.1K
Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer Kai‐Hsiung Chang, Rui Li, Mahboubeh Papari-Zareei, Proceedings of the National Academy of Sciences Dht SynthesisAndrologyUrologyDeprivation TherapyMedicine	2011	332
<i>SLCO2B1</i>and<i>SLCO1B3</i>May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer Ming Yang, Wanling Xie, Elahe A. Mostaghel, Journal of Clinical Oncology	2011	160
Common Structural and Epigenetic Changes in the Genome of Castration-Resistant Prostate Cancer Terence W. Friedlander, Ritu Roy, Scott A. Tomlins, Cancer Research	2011	122
Inherited Variation in the Androgen Pathway Is Associated With the Efficacy of Androgen-Deprivation Therapy in Men With Prostate Cancer Robert W. Ross, William Oh, Wanling Xie, Journal of Clinical Oncology	2008	107
Development of Potent and Selective Inhibitors of Aldo–Keto Reductase 1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase) Based on<i>N</i>-Phenyl-Aminobenzoates and Their Structure–Activity Relationships Adegoke O. Adeniji, Barry M. Twenter, Michael C. Byrns, Journal of Medicinal Chemistry	2012	104

Page 1